Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Liposomal Doxorubicin vs Epirubicin in Advanced Breast Cancer
NCT00431795Phase 2Terminated
- Sponsor
- Hellenic Oncology Research Group
- Start
- Jun 2003
- Primary completion
- Jun 2012
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegylated liposomal doxorubicin in breast cancer (2 arms), sponsored by Hellenic Oncology Research Group. Primary endpoint: Objective Tumor Response Rates. Started Jun 2003; status: terminated.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00431795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431795.